All In Biotech

Drug Trial Radar · NCT04768062

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 20, 2026Latest source record: Feb 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

74

Actual

Start

Apr 13, 2021

Primary completion

Oct 2025

Study completion Nov 2025

Sponsor

Lead sponsor
NS Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Nippon Shinyaku Co., Ltd.
First posted
Feb 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • ViltolarsenDrug

    Received during weekly intravenous infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment related Adverse Events as assessed by CTCAE v4.03Time frame: baseline to up to 96 weeks of treatment

Locations

31 sites in 17 countries. Site status is shown where the registry gives one.

  • Queensland Children's Hospital

    Brisbane, Australia

  • The Childrens Hospital at Westmead

    Westmead, Australia

  • CHU de Quebec Research Centre

    Québec, Canada

  • Hospital de Niños Roberto del Rio

    Santiago, Chile

  • Pontificia Universidad Católica de Chile

    Santiago, Chile

  • Chinese PLA General Hospital

    Beijing, China

  • Hunan Children's Hospital

    Changsha, China

  • Children's Hospital of Fudan University

    Shanghai, China

  • Shenzhen Children's Hospital

    Shenzhen, China

  • Fakultni nemocnice Hradec Kralove

    Nový Hradec Králové, Czechia

  • Agia Sofia Children's Hospital

    Athens, Greece

  • Hippokration General Hospital of Thessaloniki

    Thessaloniki, Greece

  • Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore

    Rome, Italy

  • National Center of Neurology and Psychiatry

    Tokyo, Japan

  • Instituto Nacional de Pediatría

    Mexico City, Mexico

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands

  • New Zealand Clinical Research Ltd.

    Auckland, New Zealand

  • Rikshospitalet

    Oslo, Norway

  • Russian National Research Medical University

    Moscow, Russia

  • "Saint Petersburg State Paediatric Medical University" based at Consultative and Diagnostic Centre

    Saint Petersburg, Russia

  • Tomsk National Research Medical Center of Russian Academy of Sciences

    Tomsk, Russia

  • Pusan National University Yangsan Hospital

    Pusan, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Hospital Sant Joan de Deu

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey (Türkiye)

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom

  • Royal Hospital for Children

    Glasgow, United Kingdom

  • Royal Manchester Children's Hospital

    Glasgow, United Kingdom

  • University College London Institute of Child Health

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.